Eurofins Scientific shares among the most sought-after in the CAC 40, +13.5% in three months
In a virtually stable CAC 40, Eurofins Scientific stands out this Monday and takes a leading position in the Paris index. The stock continues its bullish momentum initiated since mid-September, with a gain of over 13% in three months.
A rebound that keeps the stock in contact with its resistance at €78.96
Eurofins Scientific advances 1.29% to €78.36 in mid-session, in a CAC 40 practically unchanged (+0.07%). The analysis laboratory is among the strongest gainers in the CAC 40, while the session unfolds in a context of slight increase in volatility (VIX up 10.29%).
From a technical levels perspective, the stock is trading just below its resistance at €78.96, which it has not yet breached despite persistent buying pressure. The one-month performance stands at +7.34%, extending a quarterly rally of +13.63%. The RSI at 63 reflects strong bullish momentum without extreme overbought signals, leaving room before the momentum becomes excessive. The stock is furthermore well above its three moving averages: +5.96% above the 20-day MA at €73.95, and nearly 17.71% above the 200-day MA at €66.57, confirming the strength of the underlying trend.
Improving fundamentals and an anticipated acquisition to strengthen life sciences
Upon the publication of Eurofins' first-half 2026 results on July 23, 2026, management displayed marked confidence in its profitability trajectory, indicating that profitability was approaching the 2027 target more than a year ahead of schedule, with a decline in investment expenditure contributing to significantly higher cash generation. Among the development areas identified on that occasion was the acquisition of Element Materials Technology in North America, which was to bring more than 150 million dollars in annual revenues in life sciences testing services, with closing expected in the fourth quarter of 2026. The recovery of ancillary BioPharma activities, then described as expected in the second half, is another point that upcoming results will allow to verify.
In this context, the share buyback program remains active: over twelve months, Eurofins repurchased approximately 524 million euros of its own shares, representing nearly 3.8% of its market capitalization according to the latest statement consulted dated September 18, 2026. The resistance at €78.96 represents the next technical threshold that the stock will have to break to extend its momentum.
